Released Aug 10, 2020, before the open
10-Q filed Aug 10, 2020, 41 days after period end · 0001104659-20-092375
Q2 2020 · 10-Q
Revenue$10.97M$10.97M −10.5% vs Q2 2019−49.3% vs Q1 2020
Net Income-$4.15M-$4.15M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.13-$0.13 N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$2,240,000N/M
Operating Cash Flowderived-$7,835,000N/M
Free Cash Flowderived-$8,047,000N/M
Margins · derived
Operating margin-20.4%+27.3 pt vs Q2 2019
Net margin-37.8%+25.4 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $10.97M | $12.25M | $2.01M | $6.36M |
| Net Income | -$4.15M | -$7.74M | -$8.46M | $450.00K |
| EPS Diluted | -$0.13 | -$0.52 | -$0.06 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR